Attracting 60,000 Adalimumab Patients Aids Biogen

Biogen’s Total Year-To-Date Biosimilar Sales Top $500m

 
• By Aidan Fry

Rolling out its Imraldi adalimumab brand across Europe is maintaining growth in Biogen’s biosimilars franchise as sales of its Benepali etanercept drug slip back.

60000
Biogen says around 60,000 patients are now taking its Imraldi adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products